StockpollyBeta
Get App
Delisting riskPopularity #5,351Earnings are out
NCEL · NASDAQ · Biotechnology

NewcelX (NCEL)

Develops stem-cell-derived islet and astrocyte therapies for diabetes and ALS.

$2.85
vs last close−0.19 (−6.12%)

In millions of USD, except per-share figures

In millionsQ4 FY20Dec 2020Q2 FY21Jun 2021Q4 FY21Dec 2021Q2 FY22Jun 2022Q4 FY22Dec 2022Q2 FY23Jun 2023Q4 FY23Dec 2023Q2 FY24Jun 2024Q4 FY24Dec 2024Q2 FY25Jun 2025Q4 FY25Dec 2025Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
157978422243
Research & development024634000001
133333021212
Selling & marketing133333020000
General & administrative000000001210
Other expenses000000400030
Operating income−1−5−7−9−7−8−4−2−2−2−4−3
0000−10002090
Interest income000000000000
Interest expense000000000—60
Other non-operating income00000000−10−30
Income before tax−2−5−7−9−8−8−5−20−24−3
Income tax expense000000000000
Net income from continuing operations−2−5−7−9−8−8−5−20−24−3
Other adjustments000000500000
Net income−2−5−7−9−8−80−20−24−3
EPS, basic−$3.40−$4.20−$5.00−$5.40−$2.90−$2.00−$1.40−$1.94−$26.30−$10.50$1.29−$0.96
EPS, diluted−$3.40−$4.20−$5.00−$5.40−$2.90−$2.00−$1.40−$1.94−$9.90−$10.50$1.29−$0.96
Weighted average shares, basic011234343336
Weighted average shares, diluted011234343336
EBITDA−1−5−7−9−7−8—−2−2−2−1−3
Depreciation & amortization000000—00000
EBIT−1−5−7−9−7−8−4−2−2−2−1−3